Plus Therapeutics (PSTV)
(Delayed Data from NSDQ)
$1.82 USD
-0.02 (-1.09%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $1.82 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PSTV 1.82 -0.02(-1.09%)
Will PSTV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PSTV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PSTV
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
PSTV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
Other News for PSTV
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
Plus Therapeutics appoints Fuller as VP, reports $3.3M advance payment
Plus Therapeutics CMO Dr. LaFrance Resignation Announced
Plus Therapeutics files to sell 10.77M shares of common stock for holders